PURPOSE: This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). METHODS: Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to < 2 years after hospitalization) was collected. RESULTS: Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%; P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%; P < 0.001) and calcium channel blockers (21.2% vs. 28.8%; P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%; P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%; P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. CONCLUSION: The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.

Cardiology Unit Department of Medicine K2 Karolinska Institutet Stockholm Sweden

Centre for Cardiovascular Prevention 1st Faculty of Medicine and Thomayer Hospital Charles University Prague Czech Republic

Department of Cardiology Hacettepe University Ankara Turkey

Department of Internal Medicine and Pediatrics Ghent University Ghent Belgium

Department of Public Health and Primary Care Ghent University Corneel Heymanslaan 10 9000 Ghent Belgium

National Heart and Lung Institute Imperial College London London UK

National Institute for Prevention and Cardiovascular Health National University of Ireland Galway Ireland

Cardiovasc Drugs Ther. 2021 Aug;35(4):867-869. doi: 10.1007/s10557-020-07112-8. PubMed

Zobrazit více v PubMed

Piepoli MF, Abreu A, Albus C, Ambrosetti M, Brotons C, Catapano AL, et al. Update on cardiovascular prevention in clinical practice: a position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2020;27(2):181–205. DOI

Maas AH, Appelman YE. Gender differences in coronary heart disease. Neth Heart J. 2010;18(12):598–603. DOI

Maas AH, Van Der Schouw YT, Regitz-Zagrosek V, et al. Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J. 2011;32(11):1362–8. DOI

Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41(1):12–85. DOI

Dallongevillle J, De Bacquer D, Heidrich J, et al. Gender differences in the implementation of cardiovascular prevention measures after an acute coronary event. Heart. 2010;96(21):1744–9. DOI

Haider A, Bengs S, Luu J, et al. Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. Eur Heart J. 2019.

Maffei S, Guiducci L, Cugusi L, Cadeddu C, Deidda M, Gallina S, et al. Women-specific predictors of cardiovascular disease risknew paradigms. Int J Cardiol. 2019;286:190–7. DOI

Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart Association guidelines) national quality improvement initiative. J Am Coll Cardiol. 2005;45(6):832–7. DOI

Koopman C, Vaartjes I, Heintjes EM, Spiering W, van Dis I, Herings RMC, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. Eur Heart J. 2013;34(41):3198–205. DOI

Wilkinson C, Bebb O, Dondo TB, Munyombwe T, Casadei B, Clarke S, et al. Sex differences in quality indicator attainment for myocardial infarction: a nationwide cohort study. Heart. 2019;105(7):516–23. DOI

Lichtman JH, Leifheit EC, Safdar B, Bao H, Krumholz HM, Lorenze NP, et al. Sex differences in the presentation and perception of symptoms among young patients with myocardial infarction: evidence from the VIRGO study (variation in recovery: role of gender on outcomes of young AMI patients). Circulation. 2018;137(8):781–90. DOI

Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference? Am Heart J. 2004;148(1):27–33. DOI

Hiteshi AK, Li D, Gao Y, Chen A, Flores F, Mao SS, et al. Gender differences in coronary artery diameter are not related to body habitus or left ventricular mass. Clin Cardiol. 2014;37(10):605–9. DOI

Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESCEORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–35. DOI

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. DOI

Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62(19):1791–801. DOI

Asenjo RM, Bueno H, Mcintosh M. Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs) - ACE inhibitors and ARBs, a cornerstone in the prevention and treatment of cardiovascular disease. 2017. https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Treatment-goals/Cardio-Protective-drugs/angiotensin-converting-enzyme-inhibitors-ace-inhibitors-and-angiotensin-ii-rec . Accessed 15 June 2020.

Frederix I, Mcintosh M. Beta-blockers - modes of action & cardiovascular effects, indications, contraindications & side effects. 2017. https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Treatment-goals/Cardio-Protective-drugs/beta-blockers . Accessed 15 June 2020.

Krychtiuk KA, Speidl WS. Statins & more - overview of common lipid-lowering drugs used in secondary prevention to reach LDL treatment goals. 2017. https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Treatment-goals/Cardio-Protective-drugs/statins-more . Accessed 15 June 2020.

Vranckx P, Huber K. Antiplatelets therapy - antiplatelet therapy in ischemic heart disease. 2017. https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Treatment-goals/Cardio-Protective-drugs/antiplatelets-therapy . Accessed 15 June 2020.

Hilleary RS, Jabusch SM, Zheng B, et al. Gender disparities in patient education provided during patient visits with a diagnosis of coronary heart disease. Women’s Health. 2019;15:1745506519845591. PubMed PMC

Hambraeus K, Tydén P, Lindahl B. Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: data from the SWEDEHEART registry. Eur J Prev Cardiol. 2016;23(4):340–8. DOI

De Smedt D, De Bacquer D, De Sutter J, et al. The gender gap in risk factor control: effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. Int J Cardiol. 2016;209:284–90. DOI

Lahoz C, Mantilla T, Taboada M, Soler B, Tranche S, López-Rodriguez I, et al. Gender differences in evidence-based pharmacological therapy for patients with stable coronary heart disease. Int J Cardiol. 2009;133(3):336–40. DOI

Goldstein KM, Zullig LL, Bastian LA, Bosworth HB. Statin adherence: does gender matter? Curr Atheroscler Rep. 2016;18(11):63. DOI

De Smedt D, De Backer T, Petrovic M, et al. Chronic medication intake in patients with stable coronary heart disease across Europe: evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. Int J Cardiol. 2020;300:7–13. DOI

Zhao M, Vaartjes I, Graham I, Grobbee D, Spiering W, Klipstein-Grobusch K, et al. Sex differences in risk factor management of coronary heart disease across three regions. Heart. 2017;103(20):1587–94. DOI

Brugts J, Arima H, Remme W, et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Int J Cardiol. 2014;176(3):718–23. DOI

Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29(7):932–40. DOI

De Smedt D, Clays E, Annemans L, Pardaens S, Kotseva K, De Bacquer D. Self-reported health status in coronary heart disease patients: a comparison with the general population. Eur J Cardiovasc Nurs. 2015;14(2):117–25. DOI

Pogosova N, Kotseva K, De Bacquer D, et al. Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. Eur J Prev Cardiol. 2017;24(13):1371–80. DOI

Lewer D, O'Reilly C, Mojtabai R, Evans-Lacko S. Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Br J Psychiatry. 2015;207(3):221–6. DOI

Doyle F, Harpe DDL, McGee H, Shelley E, Conroy R. Gender differences in the presentation and management of acute coronary syndromes: a national sample of 1365 admissions. Eur J Cardiovasc Prev Rehabil. 2005;12(4):376–9. DOI

Worrall-Carter L, McEvedy S, Wilson A, Rahman MA. Gender differences in presentation, coronary intervention, and outcomes of 28,985 acute coronary syndrome patients in Victoria, Australia. Women’s Health Issues. 2016;26(1):14–20. DOI

Gulati M, Shaw LJ, Bairey Merz CN. Myocardial ischemia in women: lessons from the NHLBI WISE study. Clin Cardiol. 2012;35(3):141–8. DOI

Yahagi K, Davis HR, Arbustini E, Virmani R. Sex differences in coronary artery disease: pathological observations. Atherosclerosis. 2015;239(1):260–7. DOI

De Bacquer D, De Smedt D, Kotseva K, et al. Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. Eur J Epidemiol. 2019;34(3):247–58. DOI

Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–407. DOI